Business
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nTotal revenue increased 48% YoY to over $60 million\n\nRecorlev® revenue grew 141% on YoY basis\n\nTightens full-year total revenue 2025 guidance to $260 million to $275 million\n\nAnnounces upcoming Investor and Analyst Day on June 3rd in New York City\n\nHosts conference call and webcast today at 8:30 a.m. ET\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance.\n\n“We’re very pleased with our strong start to the year, delivering another quarter of outstanding revenue growth,” said John Shannon, Xeris’ Chief Executive Officer. “Our performance reflects sustained momentum across the portfolio, led by strong demand for Recorlev and is a testament to the disciplined execution of our growth strategy.” Mr. Shannon continued, “Given our exceptional first quarter performance, as well as strong continued momentum and confidence in the business, we have tightened full-year 2025 total revenue guidance to $260 million to $275 million. This revision from our previous range of $255 million to $275 million underscores the success of our strategic initiatives and our commitment to driving sustainable growth while delivering value to our patients and shareholders.”\n\nFirst Quarter 2025 Highlights\n\n\n\n \n\n\n\nThree months ended March 31,\n\n\n\n \n\n\n\nChange\n\n\n\n\n\n \n\n\n\n2025\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n$\n\n\n\n\n%\n\n\n\n\n\nProduct revenue (in thousands):\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n \n\n\n\n\n\nRecorlev\n\n\n\n$\n\n\n\n25,530\n\n\n\n \n\n\n\n$\n\n\n\n10,599\n\n\n\n \n\n\n\n$\n\n\n\n14,931\n\n\n\n \n\n\n\n\n140.9\n\n\n\n \n\n\n\n\n\nGvoke\n\n\n\n \n\n\n\n20,845\n\n\n\n \n\n\n\n \n\n\n\n16,579\n\n\n\n \n\n\n\n \n\n\n\n4,266\n\n\n\n \n\n\n\n\n25.7\n\n\n\n \n\n\n\n\n\nKeveyis\n\n\n\n \n\n\n\n11,427\n\n\n\n \n\n\n\n \n\n\n\n13,085\n\n\n\n \n\n\n\n \n\n\n\n(1,658\n\n\n\n)\n\n\n\n\n(12.7\n\n\n\n)\n\n\n\n\n\nProduct revenue, net\n\n\n\n \n\n\n\n57,802\n\n\n\n \n\n\n\n \n\n\n\n40,263\n\n\n\n \n\n\n\n \n\n\n\n17,539\n\n\n\n \n\n\n\n\n43.6\n\n\n\n \n\n\n\n\n\nRoyalty, contract and other rev...